EE200300569A - CD44v6-spetsiifilised antikehad - Google Patents

CD44v6-spetsiifilised antikehad

Info

Publication number
EE200300569A
EE200300569A EEP200300569A EEP200300569A EE200300569A EE 200300569 A EE200300569 A EE 200300569A EE P200300569 A EEP200300569 A EE P200300569A EE P200300569 A EEP200300569 A EE P200300569A EE 200300569 A EE200300569 A EE 200300569A
Authority
EE
Estonia
Prior art keywords
cd44v6
specific antibodies
antibodies
specific
Prior art date
Application number
EEP200300569A
Other languages
English (en)
Inventor
Adolf G�nther
Ostermann Elinborg
Patzelt Erik
Sproll Marlies
Heider Karl-Heinz
J. Miglietta John
Antonius Maria Silvester Van Dongen Augustinus
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals, Inc. filed Critical Boehringer Ingelheim International Gmbh
Publication of EE200300569A publication Critical patent/EE200300569A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EEP200300569A 2001-05-18 2002-05-17 CD44v6-spetsiifilised antikehad EE200300569A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (1)

Publication Number Publication Date
EE200300569A true EE200300569A (et) 2004-04-15

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300569A EE200300569A (et) 2001-05-18 2002-05-17 CD44v6-spetsiifilised antikehad

Country Status (18)

Country Link
EP (1) EP1397387A1 (et)
JP (1) JP2005504517A (et)
CN (1) CN1541226A (et)
AR (1) AR036154A1 (et)
BR (1) BR0210905A (et)
CA (1) CA2443437A1 (et)
CZ (1) CZ20033476A3 (et)
EA (1) EA200301169A1 (et)
EC (1) ECSP034838A (et)
EE (1) EE200300569A (et)
HU (1) HUP0400030A3 (et)
MX (1) MXPA03010523A (et)
PE (1) PE20021098A1 (et)
PL (1) PL365735A1 (et)
SK (1) SK15592003A3 (et)
WO (1) WO2002094879A1 (et)
YU (1) YU91403A (et)
ZA (1) ZA200307365B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP4805848B2 (ja) 2004-02-12 2011-11-02 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
WO2006116592A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EA022911B1 (ru) * 2007-06-13 2016-03-31 Займодженетикс, Инк. Способ лечения пациента, страдающего i или ii стадией системной красной волчанки
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CN102741292B (zh) 2010-02-04 2015-10-21 霍夫曼-拉罗奇有限公司 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP2024512324A (ja) * 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
JPH08506801A (ja) * 1992-11-20 1996-07-23 アイシス・イノベーション・リミテッド Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
HUP0400030A2 (hu) 2004-04-28
WO2002094879A1 (en) 2002-11-28
CN1541226A (zh) 2004-10-27
EA200301169A1 (ru) 2004-06-24
PE20021098A1 (es) 2003-02-11
SK15592003A3 (sk) 2004-06-08
CZ20033476A3 (cs) 2004-05-12
MXPA03010523A (es) 2004-07-01
AR036154A1 (es) 2004-08-18
JP2005504517A (ja) 2005-02-17
YU91403A (sh) 2006-05-25
CA2443437A1 (en) 2002-11-28
ECSP034838A (es) 2003-12-24
EP1397387A1 (en) 2004-03-17
ZA200307365B (en) 2004-05-10
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08

Similar Documents

Publication Publication Date Title
DE50204184D1 (de) Espressobrüheinrichtung
PT1411764E (pt) Cerca
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50208022D1 (de) Wischblatt
DE50206021D1 (de) Schlauchklemme
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50204386D1 (de) Kreuztransducer
DE50209238D1 (de) Kugelgelenk
ATE335486T1 (de) Hydrazono-malonitrile
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE50204551D1 (de) Kugelgelenk
DE50208372D1 (de) Schrankaufhängevorrichtung
DE50204794D1 (de) Kugelgelenk
DE50203984D1 (de) Kugelgelenk
DE50203412D1 (de) Schwenkkolbenverdränger
ATE355059T1 (de) Isoxazolopyridinone
DE50208029D1 (de) Kugelgelenk
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
DE50209293D1 (de) Amidpolymermasse
FI20011055A (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
DE50207815D1 (de) Kugelgelenk
DE50202088D1 (de) Garmodulsystem